Biotech News

Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

Pliant Therapeutics (PLRX)Pliant TherapeuticsConference / presentation

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PLN-101095 at the 41 st Annual Meeting of the Society for Immunotherapy of

Related news

Pliant Therapeutics

Integrin-Targeted Drug Discovery Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery. PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the αvβ8 and αvβ1...

Recent company news

Stock data

Close
0.62 USD
Market cap
71.83M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States